Projects per year
Abstract
Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.
| Original language | English |
|---|---|
| Pages (from-to) | 131-132 |
| Number of pages | 2 |
| Journal | Cancer Cell |
| Volume | 23 |
| Issue number | 2 |
| Early online date | 11 Feb 2013 |
| DOIs | |
| Publication status | Published - 11 Feb 2013 |
Keywords
- METFORMIN
- AMPK
- KINASE
Access to Document
Fingerprint
Dive into the research topics of 'The LKB1-AMPK Pathway-Friend or Foe in Cancer?'. Together they form a unique fingerprint.Projects
- 2 Finished
-
Rab Detection Initiative (Joint with Stanford School of Medicine, Max Plank Institute, Neuroscience Research Australia and Parkinsons Institute California)
Alessi, D. (Investigator) & Davies, P. (Investigator)
1/08/16 → 31/07/21
Project: Research
-
Non-canonical Pathways for Regulation of AMPK (Senior Investigator Award)
Hardie, G. (Investigator)
1/04/12 → 30/09/17
Project: Research